SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

LifeStance Health Group, Inc. (LFST) News

Follow LifeStance Health Group, Inc. (LFST) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 28 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol LFST Asset equity Sector Markets 90 days 25 Last 13.33 Updated Nov 05, 2026, 05:14 PM UTC Open live news feed Open LFST chart & news
M LifeStance Health Publishes Q3 2026 Earnings Call Transcript EQUITY | Nov 05, 2026, 05:14 PM UTC M Lifestance Health Group Q3 2026 Earnings Call Begins Lifestance Health Group's Q3 2026 earnings call has begun. EQUITY | Nov 05, 2026, 01:27 PM UTC M LifeStance Health Group Reports Q3 Earnings; Revenue Rises LifeStance Health Group reported third-quarter earnings, and revenue rose. EQUITY | Nov 05, 2026, 12:33 PM UTC M LifeStance Health Reports Q3 EPS of $0.06 EARNINGS | Nov 05, 2026, 11:24 AM UTC M LifeStance Health Expects 2026 Revenue of $1.74B to $1.76B LifeStance Health expects 2026 revenue of $1.74 billion to $1.76 billion, versus a FactSet estimate of $1.71 billion. EARNINGS | Nov 05, 2026, 11:23 AM UTC M LifeStance Reports Third-Quarter Results, Raises Full-Year Outlook EQUITY | Nov 05, 2026, 11:15 AM UTC M LifeStance Health Q3 Earnings Snapshot EQUITY | Nov 05, 2026, 11:13 AM UTC M LifeStance Health outlook: FY revenue USD 1,741-1,761 million The outlook is above the IBES estimate of USD 1,709 million. EARNINGS | Nov 05, 2026, 11:12 AM UTC M LifeStance Expects Q4 Revenue of $446M-$466M EQUITY | Nov 05, 2026, 11:09 AM UTC M LifeStance Health forecasts FY adjusted EBITDA of $242–250 million The outlook compares with an IBES estimate of $228.6 million. EARNINGS | Nov 05, 2026, 11:07 AM UTC M LifeStance Health Q3 Adjusted EBITDA $68.4 Million LifeStance Health reported Q3 adjusted EBITDA of $68.4 million versus the IBES estimate of $55.3 million. EARNINGS | Nov 05, 2026, 11:06 AM UTC M LifeStance Health Q3 revenue reaches $455.9 million Revenue was $455.9 million versus the IBES estimate of $431.8 million. EQUITY | Nov 05, 2026, 11:06 AM UTC M LifeStance Health Reports Q3 Net Income of $22.4 Million EARNINGS | Nov 05, 2026, 11:02 AM UTC M LifeStance Sets November 5 Date for Q3 2026 Earnings Call LifeStance says it will release third-quarter 2026 results before market open on November 5 and host a live conference call. EQUITY | Oct 15, 2026, 08:11 PM UTC H Transcript: LifeStance Health Gr Q2 2026 Earnings Conference Call LifeStance Health Gr (NASDAQ: LFST ) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial LIVE | Oct 07, 2026, 07:47 AM UTC L LFST: National leader drives growth with tech, specialty services, and margin expansion Outpatient mental health remains fragmented, but the organization leads with a national footprint and strong clinician growth. Productivity and revenue gains are driven by AI, operational improvements, and expanding spec NEWS | Sep 15, 2026, 03:42 PM UTC L LFST: Double-digit growth, tech-driven productivity, and specialty services fuel expansion and margin gains Outpatient mental health remains fragmented, but the organization leads with 8,500 clinicians and 600 centers, driving double-digit growth and productivity gains through AI and operational improvements. Specialty service NEWS | Sep 15, 2026, 03:06 PM UTC L LifeStance Health Group agrees to repurchase 2.0M shares; 22.25M shares sold by insiders LifeStance Health Group entered an underwriting agreement for an underwritten offering of 22,250,000 shares and repurchased 2,000,000 of those shares from the underwriter.Key Highlights:Original SEC Filing: LifeStance He REGULATION | Sep 11, 2026, 08:34 PM UTC L Barclays maintains LifeStance Health at Overweight EQUITY | Sep 10, 2026, 01:23 PM UTC L LifeStance Health prices secondary public offering LifeStance Health Group announced the pricing of a secondary public offering. EQUITY | Sep 09, 2026, 01:21 PM UTC L LifeStance Health Group files secondary offering of 22.25M shares Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser EQUITY | Sep 09, 2026, 12:21 PM UTC M LifeStance Health launches secondary public offering LifeStance Health Group announced the launch of a secondary public offering. EQUITY | Sep 09, 2026, 11:02 AM UTC L LifeStance CTO sold $541K of shares at $12.87 average Officer Paunovich Vukasin, Chief Technology Officer, reported selling LifeStance Health Group common stock on 2026-09-02. The weighted average selling price was $12.87 per share for 42,067 shares, totaling $541,402. EQUITY | Sep 04, 2026, 09:01 PM UTC L LifeStance management to present at upcoming investor conferences LifeStance Health Group said management will present at upcoming investor conferences, including the 2026 Jefferies Healthcare Services conference. Further conference details were not included in the provided text. EQUITY | Sep 01, 2026, 08:17 PM UTC L LFST - LifeStance to Present at Upcoming Investor Conferences LFST - LifeStance to Present at Upcoming Investor Conferences EQUITY | Sep 01, 2026, 08:10 PM UTC L LifeStance Health Gr Raises FY2026 Sales Guidance from $1.640B-$1.680B to $1.685B-$1.725B vs $1.665B Est LifeStance Health Gr (NASDAQ: LFST ) raises FY2026 sales outlook from $1.640 billion-$1.680 billion to $1.685 billion-$1.725 billion vs $1.665 billion estimate. EARNINGS | Aug 06, 2026, 10:15 AM UTC L LFST - LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook LFST - LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook EARNINGS | Aug 06, 2026, 10:00 AM UTC L LFST Reiterate Overweight, continue to like the setup ahead of Q2 but appreciate short term risk of PE overhang given recent surge in shares LFST Reiterate Overweight, continue to like the setup ahead of Q2 but appreciate short term risk of PE overhang given recent surge in shares @ BARC EQUITY | Jul 14, 2026, 11:46 AM UTC